LeMaitre Vascular, Inc. (NASDAQ:LMAT) Insider Sells $164,979.08 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT traded down $0.20 on Tuesday, hitting $84.91. The company's stock had a trading volume of 212,543 shares, compared to its average volume of 143,938. The stock has a 50 day moving average of $95.06 and a 200-day moving average of $94.64. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of 46.40, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12-month low of $62.39 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts' consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

Remove Ads

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date of this dividend is Thursday, March 13th. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's payout ratio is currently 41.24%.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC raised its position in shares of LeMaitre Vascular by 234.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its position in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 117 shares during the last quarter. KBC Group NV increased its position in LeMaitre Vascular by 58.4% during the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after purchasing an additional 410 shares during the last quarter. Huntington National Bank increased its position in LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after purchasing an additional 455 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in LeMaitre Vascular during the fourth quarter worth approximately $150,000. Institutional investors and hedge funds own 84.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LMAT shares. Lake Street Capital boosted their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.